Publikationen, an denen er mitarbeitet Iván Alejandro Ferraz Amaro (30)

2024

  1. The complement system is linked to insulin resistance in patients with systemic lupus erythematosus

    Clinical and experimental rheumatology, Vol. 42, Núm. 1, pp. 115-121

2023

  1. Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus

    Frontiers in Immunology, Vol. 14

  2. HDL Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus

    Journal of Clinical Medicine, Vol. 12, Núm. 16

  3. Hematological Composite Scores in Patients with Inflammatory Bowel Disease

    Journal of Clinical Medicine, Vol. 12, Núm. 23

  4. Tocilizumab-related hypertriglyceridemia is independent of key molecules regulating lipid metabolism

    European Journal of Clinical Investigation, Vol. 53, Núm. 9

2021

  1. Carotid plaque assessment reclassifies patients with inflammatory bowel disease into very-high cardiovascular risk

    Journal of Clinical Medicine, Vol. 10, Núm. 8

  2. Differences in Capacity of High-Density Lipoprotein Cholesterol Efflux Between Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Arthritis Care and Research, Vol. 73, Núm. 11, pp. 1590-1596

  3. HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis

    Arthritis Research and Therapy, Vol. 23, Núm. 1

  4. Impact of Disease Activity on Physical Activity in Patients With Psoriatic Arthritis

    Arthritis Care and Research, Vol. 73, Núm. 12, pp. 1834-1844

  5. Insulin resistance is not increased in inflammatory bowel disease patients but is related to non-alcoholic fatty liver disease

    Journal of Clinical Medicine, Vol. 10, Núm. 14

  6. Qrisk3 performance in the assessment of cardiovascular risk in patients with inflammatory bowel disease

    Journal of Clinical Medicine, Vol. 10, Núm. 18

2020

  1. HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients

    Clinical Rheumatology, Vol. 39, Núm. 6, pp. 1871-1880

  2. Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis

    Rheumatology (Oxford, England), Vol. 59, Núm. 10, pp. 2847-2856

  3. Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 38, pp. S18-S24

2019

  1. Effect of IL-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type-9 and Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients

    Hormone and Metabolic Research, Vol. 51, Núm. 3, pp. 200-209

2017

  1. HDL cholesterol efflux capacity in rheumatoid arthritis patients: Contributing factors and relationship with subclinical atherosclerosis

    Arthritis Research and Therapy, Vol. 19, Núm. 1

2015

  1. Relationship between endothelial dysfunction and osteoprotegerin, vitamin D, and bone mineral density in patients with rheumatoid arthritis

    Clinical and Experimental Rheumatology, Vol. 33, Núm. 2, pp. 241-249

  2. Relationship of abdominal adiposity and body composition with endothelial dysfunction in patients with rheumatoid arthritis

    Clinical and Experimental Rheumatology, Vol. 33, Núm. 4, pp. 516-523

2014

  1. Influence of disease activity on the physical activity of rheumatoid arthritis patients

    Rheumatology (United Kingdom), Vol. 53, Núm. 4, pp. 722-731

  2. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: Scientific evidence and expert opinion

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 1, pp. 1-8